EurekAlert (press release)UChicago Medicine first site in Illinois offering pioneering CAR T-cell therapy for cancerEurekAlert (press release)The treatment, known as CAR T-cell therapy, is being offered by the University of Chicago Medicine, the first … Continue reading
AGDAILYPioneer to bring CRISPR-Cas technology to Danforth Center …AGDAILYDuPont Pioneer is bringing CRISPR-Cas technology to the Danforth Center to jointly develop improved food security crops.and more »… Continue reading
Stem cell platform sheds new light on beginnings of human developmentPhys.OrgBelieved to be the first of its kind in Canada, the technology enables human embryonic stem cells to self-organize into a structure with embryo-like features, including the ea… Continue reading
|
FDA Approves CAR T-Cell Therapy for Non-Hodgkin Lymphoma
www.oncnursingnews.com/ The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) for people with large B-cell lymphoma following 2 prior therapies, including for those with diffuse large B-cell lymphoma (DLBCL). It is also … FDA Approves Yescarta™, Revolutionary CAR–T Immunotherapy for Non-Hodgkin’s Lymphoma PatientsPR Newswire (press release) FDA Approves Axi-Cel for Large B-cell LymphomaTargeted Oncology |
Friedreich’s Ataxia News |
CRISPR Therapeutics Receives FARA Grant to Develop Gene Editing Therapies for Friedreich’s Ataxia
Friedreich’s Ataxia News “We believe that the combination of CRISPR’s pioneering gene-editing capabilities with Dr. Marek Napierala’s deep expertise in FA may accelerate the development of new therapies for FA,” Jennifer Farmer, FARA’s executive director, said in a press release. |